Patent · US Active

Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

US10668072B2 · kind B2 · utility

2Cited by

81References

22Claims

0Family size

Assignee

Loxo Oncology, Inc. · US

Inventors

Mark Reynolds · Stamford, US
Steven A. Smith · Tulsa, US

Key dates

Filing date	Nov 26, 2018
Grant date	Jun 2, 2020
Priority date	—
Expiry date	Nov 26, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.